INTRODUCTION

The diagnosis of lymphoid malignancies is greatly supported and facilitated by clonality testing. Depending on the experience of the hematopathologists and the type of histopathological requests, 5–15% of cases could benefit from molecular clonality diagnostics.1,2 Of the many different markers that can be used for clonality testing in suspected lymphoproliferations, immunoglobulin (Ig) and T-cell receptor (TCR) antigen receptor gene rearrangements stand out as the most widely applied targets. These Ig and TCR rearrangements are formed from the earliest stages of B-cell and T-cell development onwards.3,4 Random coupling between one of many V, (D) and J genes results in a formation of a unique VDJ exon that encodes the actual antigen-binding moiety of the Ig or TCR chain. Owing to the huge diversity in Ig/TCR rearrangements, the diversity of different Ig or TCR molecules is estimated to be in the order of 1012. As a consequence each lymphocyte has a unique antigen receptor molecule on its membrane and the chance that two different lymphocytes coincidently bear the same receptor is almost negligible. Hence, identical rearrangements are not derived from multiple independently generated cells, but rather reflect the clonal nature of the involved cell population. Evaluation of the homogeneous vs heterogeneous nature of the rearrangements is thus at the basis of the clonality testing.

In the last two decades, PCR-based analysis of Ig/TCR rearrangements has gradually replaced Southern blot analysis as a standard method for clonality assessment.5-9 The result of such an analysis is a representation of the rearrangement events present in a single cell. Since all clonally related cells are assumed to carry identical rearrangements, clonality testing is based on the comparison of clonal to non-clonal patterns. PCR-based analysis of Ig/TCR rearrangements is the most generally applied clonality test in patients with suspected lymphoproliferations.10-12

Molecular clonality is based on the evaluation of molecular patterns.13,14 These Ig and TCR rearrangements are formed from the earliest stages of B-cell and T-cell development onwards. The technical description of individual (multiplex) PCR reactions and the overall molecular conclusion for B and T cells. Collectively, the EuroClonality (BIOMED-2) guidelines and consensus reporting system should help to improve the general performance level of clonality assessment and interpretation, which will directly impact on routine clinical management (standardized best-practice) in patients with suspected lymphoproliferations.

EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations

AW Langerak1, PJTA Groenen2, M Brüggemann3, K Beldjord4, C Bellan5, L Bonello6, E Boone7, GI Carter8, M Catherwood9, F Davi10, M-H Delfau-Larue11, T Diss12, PAS Evans13, P Gameiro14, R Garcia Sanz15, D Gonzalez16, D Grand17, Å Håkansson18, M Hummel19, H Liu20, L Lombardia21, EA Macintyre22, BJ Milner23, S Montes-Moreno24, E Schuuring25, M Spaargaren26, E Hodges27 and JJM van Dongen28

PCR-based immunoglobulin (Ig)/T-cell receptor (TCR) clonality testing in suspected lymphoproliferations has largely been standardized and has consequently become technically feasible in a routine diagnostic setting. Standardization of the pre-analytical and post-analytical phases is now essential to prevent misinterpretation and incorrect conclusions derived from clonality data. As clonality testing is not a quantitative assay, but rather concerns recognition of molecular patterns, guidelines for reliable interpretation and reporting are mandatory. Here, the EuroClonality (BIOMED-2) consortium summarizes important pre- and post-analytical aspects of clonality testing, provides guidelines for interpretation of clonality testing results, and presents a uniform way to report the results of the Ig/TCR assays. Starting from an immunobiological concept, two levels to report Ig/TCR profiles are discerned: the technical description of individual (multiplex) PCR reactions and the overall molecular conclusion for B and T cells.

Collectively, the EuroClonality (BIOMED-2) guidelines and consensus reporting system should help to improve the general performance level of clonality assessment and interpretation, which will directly impact on routine clinical management (standardized best-practice) in patients with suspected lymphoproliferations.

Keywords: immunoglobulin; T-cell receptor; clonality; guideline; lymphoid malignancies
gold standard method for clonality testing.\textsuperscript{15-18} However, the earliest PCR strategies suffered from false negativity (lack of recognition of all possible rearrangements) and false positivity (inability to accurately distinguish monoclonal from polyclonal PCR products). False negativity was at least in part also caused by the fact that most laboratories only used TCR gamma (TCRG) and complete IG heavy chain (IGH) V–J gene rearrangements as PCR targets for reasons of limited primer usage and relatively simple gene structure. These drawbacks prompted the design of completely novel assays for Ig/TCR rearrangement detection in the European BIOMED-2 network (now called EuroClonality consortium).\textsuperscript{15} This effort has resulted in standardized multiplex PCR assays for nearly all Ig/TCR targets, which collectively show an unprecedentedly high rate of detection in the most common B- and T-cell malignancies.\textsuperscript{15-18} This high detection rate was not only achieved by optimized primer design, but also by inclusion of extra Ig/TCR targets (IG kappa, IGK and TCR beta, TCRB as well as incomplete IGH D–J and TCRB D–J rearrangements).\textsuperscript{15} Meanwhile, the BIOMED-2/EuroClonality PCR protocols have been extensively validated in studies of many groups outside the consortium.\textsuperscript{19-22} As a result these multiplex assays have now become the world standard for PCR-based Ig/TCR clonality testing.

Owing to the successful development of the BIOMED-2/EuroClonality multiplex PCR protocols, the analytical phase of clonality testing has thus largely been standardized. Because of this standardization, Ig/TCR clonality testing has now become routine for the first time in a routine diagnostic setting. This is reinforced by the availability of commercial kits to run these assays (InVivoScribe, San Diego, CA, USA). An important consequence of the technical standardization and commercialization is that clonality assays can easily be performed in routine laboratories, even in (smaller) laboratories that only occasionally receive clonality testing requests, and thus have limited experience. However, background knowledge and ample experience are more than ever required for Ig/TCR target choice and accurate interpretation of the PCR results.\textsuperscript{23} In an attempt to make interpretation less subjective, interpretation algorithms have been introduced, especially in the United States.\textsuperscript{24-26} These algorithms take into account peak heights and peak ratios to define ‘truly clonal’ rearrangements. Although clear clones readily fulfill such criteria, the cutoff values used in these algorithms create a false sense of accuracy and might even lead to false-positive or false-negative interpretation. The main problem is that multiplex clonality PCRs, which use primers of different efficiencies, are not quantitative, but merely qualitative assays. Thus, clonality testing much more concerns recognition of molecular patterns, for which accurate interpretation and reporting guidelines are mandatory. Hence, standardization of the pre-analytical and post-analytical phases is urgently needed to prevent misinterpretation and incorrect conclusions of the clonality data obtained.

For this reason standardization of interpretation and quality control are major aims of the EuroClonality consortium, next to education and further innovation in molecular hemat-oncology (see: http://www.euroclonality.org). This is being done in an external quality assessment (EQA) scheme for Ig/TCR clonality testing, the need for guidelines on how to interpret and report Ig/TCR clonality data has become even more apparent, given the lack of objective criteria to evaluate Ig/TCR data. During recent years, the EuroClonality group has therefore been working on standardization of pre- and post-analytical aspects, including the development of clear guidelines for analysis, interpretation and reporting of the EuroClonality (BIOMED-2) Ig/TCR assays.

Here, we discuss important pre- and post-analytical aspects of clonality testing, provide guidelines for interpretation of clonality results and present a uniform way to report the results of Ig/TCR assays. Collectively, these aspects should help to improve the general performance level of clonality assessment and interpretation, which will directly impact on routine clinical management (standardized best-practice) in patients with suspected lymphoproliferations.

**PRE-ANALYTICAL PHASE**

In the pre-analytical phase several aspects are of utmost importance for optimal clonality testing results. These include the clinical context, selection of representative material, preservation and sample handling, isolation of nucleic acid (yield, purity and integrity) and selection of Ig/TCR rearrangements as PCR targets.

Material type and sample preparation

 Particularly relevant for final interpretation is key information on the suspected cell population. This information should come from either (histo)morphology/immunohistochemistry and/or flow cytometric immunophenotyping, and typically concerns the suspected cell lineage and the tumor size, as well as the background of non-suspicious (normal or reactive) lymphoid cells. It is obvious that the performance of the multiplex Ig/TCR clonality assays is highest with fresh or frozen cell material, as these PCR assays have been validated and standardized for that type of material. However, the use of formalin-fixed paraffin-embedded (FFPE) tissues has also proven to be a realistic option,\textsuperscript{27} provided that the DNA is not too degraded. Although most nucleic acid isolation procedures (traditional methods and/or kits) generally result in a good yield and purity, it might be important to further purify the DNA isolated from FFPE blocks to remove PCR inhibitors. Because of the inhibitory effect, it is advised to test FFPE DNA at different concentrations (at least two) in the Ig/TCR multiplex PCRs. In this respect, FFPE DNA integrity should be checked upfront to adapt the concentration used in the Ig/TCR assay. In contrast, fresh or frozen tissue is sufficient to check DNA integrity afterwards, only when unexpected negative results are obtained in the Ig/TCR tests. DNA integrity can be checked via one of many available PCRs that target a single gene. Though these control tests might have their value, the BIOMED-2 control gene test, being a multiplex assay of differently sized amplicons, is preferred as it probably best reflects the multiplex conditions under which the actual Ig/TCR clonality tests are run\textsuperscript{15} and provides a good view of the product sizes that can be expected to be amplified properly. Given the amplicon size of most Ig/TCR targets, amplification of fragments of 300 nucleotides (nt) in the control PCR predicts reliable Ig/TCR testing results. Nevertheless, even when amplicons of maximally 200 nt are obtained, smaller Ig/TCR amplicons might still be evaluated reliably (Table 1).\textsuperscript{18}

Selection of targets

Once the DNA quality is checked and approved, the next important aspect of the pre-analytical phase concerns the selection of the Ig/TCR targets to be evaluated. Target selection typically depends on the amount of available DNA, the DNA integrity and naturally the clinical question, including the type of suspected clonality assay. If the DNA amount and integrity are not limiting factors, target selection is solely determined by the clinical question.

In the EuroClonality network, an algorithm for target selection has been proposed that depends on the suspected cell population (Figure 1).\textsuperscript{21} Thus, in case of suspected B-cell clonality, generally the three different IGH FR targets are chosen, in parallel to or followed by the IGK targets.\textsuperscript{17} Although the consecutive use of IGH and IGK PCRs might be the more cost-efficient approach,\textsuperscript{21} a parallel approach is more cost-effective for both the clinician and the patient. Even though the combination of IGH V–J and IGK targets should be sufficient in the vast majority of cases (>95%), evaluation of the IGH D–J and IGL targets might occasionally be
helpful as second-line approach. The use of TCRD in other situations merely creates difficulties due to its small CDR3 and, thus, the paucity of TCRD templates might easily give rise to false-negative results.

**Table 1.** Ig/TCR multiplex PCR: preferred method of analysis, expected size ranges and nonspecific bands

| Multiplex PCR | Preferred method of analysis | Size range (nt) | Nonspecific bands (nt) |
|---------------|------------------------------|----------------|-----------------------|
| IgH V_{H}–J_{H} | GS and HD both suitable | Tube A: 310–360 | Tube A: ~ 85 |
| TCRB | GS and HD both suitable | Tube B: 250–295 | Tube B: ~ 229 |
| IGK | GS and HD both suitable | Tube C: 100–170 | Tube C: ~ 211b |
| IGL | HD slightly preferred over GS | Tube D: 110–290 (D_{H}1/2/4/5/6-J_{H}) | Tube D: ~ 350c |
| IGK Kde | GS and HD have complementary value | Tube E: 100–130 | Tube E: 211d |
| TCRB | GS and HD both suitable | Tube F: 210–250 V_{H}1/6/V_{K}7-J_{H} 270–300 (V_{H}3f/intron-Kde) | Tube F: ~ 217b |
| TCRG | GS and HD both suitable | Tube G: 350–390 (V_{H}2f/V_{K}4/V_{K}5-Kde) | Tube G: ~ 404f |
| TCRD | HD slightly preferred over GS | Tube A: 140–165 | Tube A: -- |
| IGHD | HD slightly preferred over GS | Tube B: 240–285 | Tube B: ~ 213b,h, ~ 273b |
| IGK | GS and HD both suitable | Tube C: 170–210 (D_{H}J_{H}) 285–325 (D_{H}J_{H}) | Tube C: ~ 93, ~ 126, ~ 221h,a |
| TCRD | HD slightly preferred over GS | Tube A: 145–255 | Tube A: -- |
| TCRB | GS and HD both suitable | Tube B: 80–220 | Tube B: -- |
| TCRG | GS and HD both suitable | Tube D: 120–280 | Tube D: ~ 90, ~ 123 |
| IGK Kde | GS and HD both suitable | Tube E: 170–210 (D_{H}7–J_{H}2) | Tube E: -- |
| IGL | HD slightly preferred over GS | Tube F: 100–170 (V_{K}2f/V_{K}3f/intron-Kde) | Tube F: -- |
| TCRB | GS and HD both suitable | Tube G: 120–160 (V_{K}7/J_{H}2) | Tube G: -- |
| TCRG | GS and HD both suitable | Tube H: 310–360 (V_{H}3f-intron-Kde) | Tube H: -- |
| TCRD | HD slightly preferred over GS | Tube I: 390–420 (D_{H}3–J_{H}3) | Tube I: -- |
| IGK | HD slightly preferred over GS | Tube J: 120–160 (V_{K}7/J_{H}2) Tube K: 90, 123 |
| TCRB | GS and HD both suitable | Tube L: 240–285 | Tube L: ~ 213b,h, ~ 273b |
| IGK Kde | HD slightly preferred over GS | Tube M: 210–250 V_{H}1/6/V_{K}7-J_{H} 270–300 (V_{H}3f/intron-Kde) | Tube M: ~ 93, ~ 126, ~ 221h,a |
| IGL | HD slightly preferred over GS | Tube N: 140–165 | Tube N: -- |
| TCRB | GS and HD both suitable | Tube O: 240–285 | Tube O: ~ 213b,h, ~ 273b |
| IGK Kde | HD slightly preferred over GS | Tube P: 170–210 (D_{H}J_{H}) 285–325 (D_{H}J_{H}) | Tube P: ~ 93, ~ 126, ~ 221h,a |
| TCRG | GS and HD both suitable | Tube Q: 145–255 | Tube Q: -- |
| TCRD | HD slightly preferred over GS | Tube R: 80–220 | Tube R: -- |
| IGK | HD slightly preferred over GS | Tube S: 120–280 | Tube S: ~ 90, ~ 123 |

**Abbreviations:** GS, GeneScan; HD, heteroduplex; Ig, immunoglobulin; IGH, IG heavy chain; IGK, IG kappa; IGL, IG lambda; nt, nucleotide; TCR, T-cell receptor; TCRB, TCR beta; TCRD, TCR delta; TCRG, TCR gamma. Update of table 25 of earlier BIOMED-2/EuroClonality report. Particularly seen in samples with low numbers of contaminating lymphoid cells. The 211-bp PCR product represents product from germline D_{H}7–J_{H}1 region; when PCR amplification is very efficient, also longer PCR products might be obtained based on primer annealing to downstream J_{H} genes; for example, 419 bp (D_{H}5–J_{H}2), 1031 bp (D_{H}2–J_{H}3). See also Table 2. Detection of nonspecific band depends on quality of primers (batch-dependent)

**Technical pitfalls**

- Reproducibility of the profiles is essential. The number of lymphocytes in, for example, skin or intestinal lesions can easily result in overinterpretation of coincidental dominant peaks.
- To prevent misinterpretation, assessment of the targets in duplicate as well as adjustment of the amount of DNA by increasing the DNA concentration, and hence the number of cells per PCR, are strongly recommended.

**POST-ANALYTICAL PHASE: PITFALLS AND SOLUTIONS**

Accurate interpretation and reporting of clonality testing results depends on detailed knowledge on the structure of Ig/TCR genes, their rearrangement patterns and awareness of all nonspecific amplifications and cross-lineage rearrangements. Many of these issues have been addressed extensively over the years in multiple publications on behalf of the EuroClonality group. Recently, even a whole issue of the *Journal of Hematopathology* was devoted to multiple aspects of clonality testing.

*Technical pitfalls*

- If no PCR products (that is, neither clonal nor polyclonal products) are obtained in the multiplex PCR, it is worth checking the reproducibility of the profiles. A low number of lymphocytes in, for example, skin or intestinal lesions can easily result in overinterpretation of coincidental dominant peaks. To prevent misinterpretation, assessment of the targets in duplicate as well as adjustment of the amount of DNA by increasing the DNA concentration, and hence the number of cells per PCR, are strongly recommended.
interpretation and alternative strategies. Lack of Ig/TCR (monoclonal and polyclonal) products because of poor DNA quality of the FFPE tissue can be confirmed by checking DNA quality in a control gene multiplex PCR (see above). Furthermore, B- and T-cell numbers can be rechecked using histological slides or flow cytometry data to understand whether the lack of detectable PCR products is caused by lack of B or T cells in the sample. If so, an alternative specimen should be analyzed. For B-cell clonality it is important to verify whether the patient has received CD20 antibody therapy. Finally, extensive somatic mutation in Ig genes might prevent optimal annealing of Ig primers and thus block efficient amplification of the clonal Ig rearrangement. In such cases, alternative Ig targets that are less prone to somatic hypermutation (IGH D–J, IGK Kde rearrangements) should be evaluated (concept of complementarity of targets).\(^ {15,17,38}\) False-negative results can also be caused by the presence of t(11;14) and t(14;18) aberrations in mature B-cell proliferations. As these aberrant Ig rearrangements are not amplified in the IGH multiplex PCRs, an IGH V–J PCR failure could be expected from such alleles. Thus, information concerning complementary laboratory tests (for example, fluorescence in situ hybridization analysis) should be taken into account when interpreting clonality data.

Based on primer positions and the expected extent of nt insertion at the junctions, amplicon size ranges were previously established for all Ig/TCR multiplex PCR reactions (Table 1).\(^ {16,39,40}\) However, as these size ranges represent the approximate 5–95% intervals, amplicons that are a few nts shorter or longer may still represent true rearrangements. Even clearly undersized or oversize amplicons may be considered as true rearrangements in the absence of evidence of nonspecific products in other samples,\(^ {36,41}\) especially in IGH and IGK targets that harbor deletions and insertions through the somatic hypermutation process.\(^ {41}\) Also, amplification from a downstream J gene might create extended PCR amplicons, which could occur as an additional PCR product in the same or the another V–J multiplex reaction (in case of TCRB, IGH and IGK) or as the sole PCR product (in case of IGH and IGK).\(^ {36,42}\) In the latter situation, this is mostly due to disrupted primer annealing to the J gene of the V(D)J junction owing to the

---

**Figure 1.** Strategy for PCR-based clonality diagnostics in suspected lymphoproliferations with an inconclusive diagnosis or with unusual histology, immunophenotype or clinical presentation, using the EuroClonality/BIOMED-2 multiplex PCR protocols. In case of a suspected B-cell proliferation, IGH VH–JH multiplex PCR analysis is best performed first. As a second step, IGK PCR analysis (Vκ–Jκ and Kde rearrangements) can be chosen. Preferably, these two steps are combined to avoid delay in the diagnostic process. Finally, IGH D\(_H\)1–6–JH PCR analysis (potentially combined with IGL analyses) can be reserved for remaining suspected cases, in which the preceding PCR assays have failed to detect monoclonality and have not shown clear signs of polyclonality either. For suspected T-cell proliferations, TCR multiplex PCR is generally slightly more informative than TCRG PCR, but the order of analysis of these two loci can be changed as they provide complementary information; preferably both targets should be used in parallel. Only in case of suspected TCR\(_{\gamma\delta}\) T-cell proliferations and immature T-cell proliferations (suspicion of lymphoblastic malignancies), combined TCRG and TCRD PCR analysis is preferred. In case of suspected lymphoproliferations of unknown origin, both Ig and TCR genes should be used as PCR targets. It should be noted that in such cases the clonal Ig/TCR results cannot be used straightforwardly for B-/T-lineage assignment. A full-proof diagnosis of polyclonality remains difficult, but a high probability of polyclonality is supported by clear Gaussian GS curves or HD smears in the absence of clonal results.
somatic mutations. Furthermore, in some cases multiple peaks/bands are observed that result from the same IGK V–J rearrangement, which is explained by some cross-annealing of V family-specific primers to genes of other V families and the fact that bands are observed that result from the same IGK V–J rearrangement. Moreover, in some cases multiple peaks/bands have been described before, recently some novel nonspecific products have been found. Therefore, we have now updated the original information of the 2003 publication in Table 1.

Table 2. Technical and biological pitfalls in Ig/TCR clonality testing

| Phenomenon                                                                 | Pitfall                                                                 | Potential solution                                                                 |
|---------------------------------------------------------------------------|-------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Lack of clonal signal and lack of polyclonal Gaussian curve               | Poor DNA quality                                                        | 1. Check DNA quality in control PCR                                              |
|                                                                           | Few T/B cells                                                           | 2. Check T/B-cell content by histology or flow cytometry                         |
|                                                                           | Clonal signal not detected due to SHM in malignant cells                | 3. Evaluate other framework or Ig target                                           |
| Bands/peaks outside size range                                           | CDR3 regions/junctions outside 5–95% size interval                     | 1. True rearrangement product; in case of doubt, sequence for confirmation         |
|                                                                           | Non-specific product                                                    | 2. Check Table 1 for sizes of nonspecific products                              |
| Undersized bands/peaks                                                  | For example, internal deletion in VH/Vk/Vj gene (SHM related)           | Potential rearrangement product; sequence for confirmation                         |
| Oversized bands/peaks                                                   | For example, extended amplification from downstream J gene (for example, | Potential rearrangement product; sequence for confirmation                         |
|                                                                           | SHM in rearranged JH gene                                               |                                                                                  |
| Multiple clonal signals                                                 | Bi-allelic rearrangements                                               | Consider the number of potential rearrangements per allele/locus and judge whether this fits with clonality (with biallelic rearrangements) or biclonality |
| Selective amplification and pseudo-clonality, due to low level of specific template | Few T/B cells in sample                                                 | Repeat multiple PCRs (same tissue, second independent DNA isolation and/or related tissue) → compare patterns for consistency |
| Oligo-/monoclality in histologically reactive lesion                      | Exaggerated immune response with dominant specificity (for example, large germinal centers) | 1. Repeat multiple PCRs (same tissue, second independent DNA isolation and/or related tissue) → compare patterns for consistency between samples and multiple targets |
| Oligoclonal T-/B-cell repertoire in peripheral blood of elderly individuals, immunodeficient patients or transplant patients | Incomplete immune system, for example, in case of immunosenescence or reduced/ suppressed lymphocyte production | 2. Re-evaluate histopathology → repeat multiple PCRs (same tissue, second independent DNA isolation and/or related tissue) → compare patterns for consistency and compare with primary process (in case of staging) |

Abbreviations: CDR, complementarity-determining region; HD, heteroduplex; Ig, immunoglobulin; IGK, IG kappa; SHM, somatic hypermutation; TCR, T-cell receptor; TCRB, TCR beta. aNonspecific peak(s)/band(s) might be observed. bClone of unknown significance is mostly seen under conditions in which there is some residual background of polyclonal cells. cNumber of peaks/bands is dependent upon biological conditions. dRepresents false-negative result.

Table 3. Typical expected Ig/TCR profiles under different immunobiological conditions

| Immunobiological condition | Examples                                                                 | Expected profile in PCR reaction                                                                 |
|----------------------------|-------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| No lymphocytes             | Non-hematopoietic tissue                                               | No peaks/bands (w/o background)                                                                  |
| Paucity of lymphocytes     | Small infiltrate, small sample (for example, skin)                     | (Minor) peaks/bands, not reproducible                                                            |
| (Immune)activation with dominant clones                               | Dominant immune response (for example, infection, autoimmunity)          | (Multiple) peaks/bands, reproducible                                                              |
| Reactive lymphocytes       | Broad immune response                                                   | (Irregular) Gaussian curve/smear                                                                  |
| Monoclonality (mono-/bi-allelic)                                     | Leukemia, lymphoma, (clone of unknown significance)                      | One or two peaks/bands                                                                            |
| Monoclonality + polyclonal background                                 | Idem, (small) clone between normal/reactive lymphocytes                   | Two or one peaks/bands + Gaussian curve/smear                                                      |
| Monoclonality (somatically mutated)                                   | Idem, (post-)follicular B-cell process                                  | No peaks/bands (or Gaussian curve/smear from remaining normal lymphocytes)                       |

Abbreviations: Ig, immunoglobulin; IGK, IG kappa; TCR, T-cell receptor; TCRB, TCR beta. *Non-specific peak(s)/band(s) might be observed. *Clone of unknown significance is mostly seen under conditions in which there is some residual background of polyclonal cells. Number of peaks/bands is dependent upon competition in PCR reaction; for IGK and TCRB loci up to four clonal products may be compatible with one clone. *Represents false-negative result.

Biological pitfalls

Beside the technical issues, also multiple biological pitfalls can pose difficulties in interpretation of clonality testing results. These pitfalls not only concern immunobiological aspects, but also locus-intrinsic aspects.

Translating the number of apparently clonal peaks into the number of clones is not always straightforward. Most lymphocytes undergo rearrangements on both alleles of a particular Ig or TCR locus. Hence, two clonal peaks are more likely to reflect biallelic rearrangement patterns than biclonality. Nonetheless, true biclonality can occur in up to 5% of mature B-cell lymphoproliferative disorders, and in these cases careful interpretation of IGH/IGK rearrangement patterns must be performed in conjunction with morphology, immunophenotyping...
and/or immunohistochemistry. Furthermore, because of the specific configuration of some Ig/TCR loci (especially IGK and TCRB), multiple rearrangements can be present on the same allele. Consequently, this will have an impact on defining the number of clones, as the presence of up to four different IGK or TCRB rearrangements is still compatible with a single clonal cell population (explained in detail in Langerak et al.35).

Additional immunobiological aspects to be considered when interpreting Ig/TCR clonality data, have to do with the number of lymphocytes, in the sample and with the immune reactivity under inflammatory or ageing conditions. The presence of only few B or T cells in the sample (for example, in skin tissues) might cause preferential amplification, leading to the false impression of monoclonality (pseudoclonality). This stresses the importance of evaluating duplicate PCR reactions to establish reproducibility of clonality patterns and products. Under certain conditions (infection and inflammation) multiple clonal peaks might be present as a result of an exaggerated immune response. These immune response-related clonal expansions of lymphocyte populations should not be misinterpreted as signs of malignancy. Detection of an oligoclonal T-cell repertoire in the blood of elderly individuals and immunodeficient patients or transplant patients should be considered as potential sign of an incomplete immune system due to ageing of the system (immunosenescence) and reduced or suppressed T-cell production, respectively. The same might apply to the B-cell repertoire in an ageing immune system, though possibly to a lesser extent.

**EXTERNAL QUALITY ASSESSMENT**

To ensure correct performance and accurate interpretation of results in laboratories performing Ig/TCR clonality assays, a robust EQA scheme is an essential instrument. The initial challenge was therefore to standardize EQA for clonality analysis among EuroClonality laboratories and to develop guidelines for analysis, interpretation and reporting of clonality testing results.

In the first five EQA rounds that were organized in the EuroClonality network, the performance of BIOMED-2-based Ig/TCR clonality assessment was tested using DNA samples from different hematological and histopathological cases. As readout systems both GeneScan (GS) fragment analysis and polyacrylamide heteroduplex (HD) analysis were used.15 Cases in the various EQA rounds were selected by the individual EQA participants. These electronic data files and images allowed a more accurate assessment of the reproducibility of interpretation.

**Table 4. The EuroClonality uniform system for technical description**

| Type of profile per tube (in duplicate) | Technical description per tube | Optional: more detailed technical description
|----------------------------------------|-------------------------------|----------------------------------|
| No peaks/bands (but: poor DNA quality) | No (specific) product, poor DNA quality | Non-specific product(s) (... nt) |
| No peaks/bands (w/o background)       | No (specific) product          |                                  |
| One or two reproducible clonal peaks/bands | Clonal (... nt) | Weak clonal (... nt) |
| One or two non-reproducible (clear) peaks/bands | Pseudoclonal | Pseudoclonal |
| Multiple (n ≥ 3) non-reproducible peaks/bands | Multiple products (n = ...) (... nt) |                                  |
| Gaussian curve/smear (with or without minor reproducible peaks/bands) | Polyclonal (not clonal) | Irregular polyclonal (not clonal) |

**Pattern that cannot be categorized as one of the above** Not evaluable

Abbreviations: HD, heteroduplex; nt, nucleotide. *Examples of more detailed technical description options that can be chosen by the user.* In HD analysis the number of bands does not necessarily reflect the number of different PCR products, as additional HDs can be formed between products. In HD analysis a polyclonal smear may not always be smooth or clear, despite specific product in gel; hence this is scored as ‘not clonal.’ In <3% of PCR results the description per tube cannot be made.

**Figure 2.** Example highlighting the difficulty to correlate the number of bands in HD analysis to the number of rearrangements. Using TCRG multiplex PCR tube A, two clonal peaks are observed (biallelic rearrangements) in GS analysis (a). In contrast, in HD analysis (b) four bands are seen, two representing the homoduplexes of ~144 and ~216 bp, and the other two representing clonal HDs between the two clonal rearrangements (indicated by arrows).
process of developing a standardized technical description of clinical data. Therefore, from the first EQA round onwards, a testing results with morphological, immunophenotypical and/or clinical data, standardization of level 3 was considered to be beyond the scope of EuroClonality. Finally, the revised standardized description system was evaluated by each EuroClonality center using 50 consecutive routine diagnostic cases that were submitted for Ig/TCR clonality testing.

Immunobiological concept as starting point
To create a conceptual basis for the proposed EuroClonality uniform description and reporting of clonality data, we first defined the typical Ig/TCR profiles that could be expected in particular immunobiological conditions (Table 3). Notably, reproducibility of the profiles is an important aspect of this conceptual basis. We therefore strongly advocate the use of duplicates (independent PCR amplifications from the same DNA isolate, or from a second DNA isolate), such that results from the duplicate analyses can be taken into account. In our view and experience having the results from duplicate experiments is pivotal for accurate interpretation of the molecular profiles.

In DNA samples from a specimen without lymphocytes, no rearranged Ig/TCR genes are to be expected. This implies that in such samples no specific Ig/TCR amplicons can be formed, however, it should be realized that nonspecific PCR products of the multiplex assays might become more easily amplified in such samples (Table 1). When few lymphocytes are present in the specimen (so called paucicellular specimens), for example, in a case of a small lymphocyte infiltrate in a skin sample, selective amplification might occur. This is due to a nonrandom distribution of DNA template in the aliquot that is used in the PCR reaction. The resulting Ig/TCR profile will show several peaks or bands that are not reproducible in duplicates. In specimens with numerous reactive lymphocytes an Ig/TCR profile with a more or less complete Gaussian distribution is to be expected, whereas a dominant immune response might create (multiple) peaks/bands that are reproducible in duplicates. Finally, the presence of a monoclonal population of lymphocytes, as in a lymphoid malignancies or as a clone of unknown significance, is predicted to give rise to one or two clear (reproducible) peaks or bands (monoallelic and mostly biallelic rearrangements, respectively), possibly in combination with a polyclonal Gaussian profile of the non-clonal reactive lymphocytes. It should be noted that for some targets (IGH, TCRB and TCRG) the presence of clear, monoclonal peaks/bands in one multiplex PCR reaction might result in lack of specific Ig/TCR amplicons in the complementary multiplex PCR targeting the same locus, owing to the lack of remaining reactive lymphocytes. An exceptional situation could be expected in the case of B-cell clones that show a heavy somatic mutation load, in which case the monoclonal product would remain undetected resulting in a Gaussian Ig profile (when reactive cells are present in the background) or a profile without Ig peaks/bands (in case of a high tumor load without reactive cells).

Technical description of individual multiplex PCR reactions
Based on the expected profiles presented in Table 3, we defined a list of technical descriptions for the expected profiles (level 1 of post-analytical interpretation). These technical descriptions are primarily meant to standardize reporting and interpretation within and between laboratories. Nevertheless, these descriptions sometimes appear on the final report to the clinician or pathologist. At first we started with an extensive list of technical descriptions taking into account all kind of subtleties, but gradually this list shortened, as it appeared to be too difficult to find consensus on

EUROCLONALITY UNIFORM DESCRIPTION AND REPORTING OF IG/TCR DATA
The post-analytical phase of diagnostic PCR-based clonality testing comprises three different levels, (1) technical description per PCR; (2) overall molecular interpretation of clonality testing data (separate for Ig and TCR); and (3) integration of the clonality testing results with morphological, immunophenotypical and clinical data. Therefore, from the first EQA round onwards, a process of developing a standardized technical description of individual multiplex tubes (level 1) was started. In the later EQA rounds the uniform technical description was further refined to a standardized reporting system. In parallel, reporting of the overall molecular interpretation of Ig and TCR clonality data (level 2) was also standardized. As clinical interpretation is dependent upon morphological, immunophenotypical and/or clinical data, standardization of level 3 was considered to be beyond the scope of EuroClonality. Finally, the revised standardized description system was evaluated by each EuroClonality center using 50 consecutive routine diagnostic cases that were submitted for Ig/TCR clonality testing.
distinguishing between several of the more subtle terms. After four EQA rounds, we therefore agreed to make a more limited series of consensus technical descriptions that should clearly distinguish between the main profiles of the multiplex PCRs (Table 4). To describe additional aspects of the profiles, we agreed to have the option of a more detailed description in addition to the main description category. The uniform system for technical descriptions was intended for both GS fragment analysis and gel-based HD analysis, however, it appeared that some of the options are clearly applicable to GS analysis but are not very suitable for describing HD results (Table 4).

When applying these descriptions in daily practice, profiles without peaks/bands will be referred to as ‘no (specific) product’, with the possibility to indicate that DNA quality appeared to be poor. Optionally, nonspecific PCR products and their amplicon sizes are mentioned. Profiles with one or two clear peaks or bands are called ‘clonal’, with the option to indicate that the intensities are weak or that a polyclonal background is seen. Even cases that show a relatively weak clonal peak/band in a polyclonal background can be truly clonal, as long as the pattern is reproducible and preferably seen in multiple targets. When one to two peaks or bands are identified that are clearly non-reproducible, this is referred to as ‘pseudoclonal’; implicit in this description is that clonal signals are seen, but that they differ in size between the duplicates. Profiles with multiple (defined as three or more) peaks or bands are indicated with the description ‘multiple products’. Such profiles can be non-reproducible or reproducible; the former option is very close to ‘pseudoclonal’, whereas the latter reflects multiple consistent clones probably due to a dominant immune response. It should be noted that in HD analysis the number of bands is not necessarily equal to the number of rearrangements due to the presence of both homoduplex band(s) as well as HD band(s) formed between the different rearrangements (Figure 2).

The Gaussian profile in GS analysis and the smear in HD analysis are described as ‘polyclonal’, although the HD smear may not always be clearly visible in which case this profile is best referred to as ‘not clonal’. If the Gaussian distribution is not perfectly shaped (especially in GS analysis), the option ‘irregular polyclonal’ can be used to more accurately describe a profile that is largely polyclonal with some minor peaks. Finally, any profile that cannot be categorized as one of these categories should be referred to as ‘not evaluable’. One example might be those profiles in which the signal intensity is in the range of background noise.

To illustrate the main technical descriptions of the various Ig/TCR profiles in GS analysis, we have selected several routine diagnostic cases that showed representative profiles for one or more of the Ig/TCR loci (Figures 3–8).

Molecular conclusion on Ig/TCR gene rearrangement pattern
Based upon the results of the individual PCR targets and using the knowledge of the Ig/TCR loci, the molecular conclusion on the Ig/TCR rearrangement pattern is defined.

Analogous to the list of technical descriptions, we also started with a long list of overall molecular interpretations and conclusions of clonality testing results (level 2 of post-analytical interpretation). These molecular interpretations are based on the technical descriptions of all available Ig/TCR profiles, dealing with B and T cells separately. It should be noted that that cross-lineage rearrangements may occur occasionally, and with high frequency in immature lymphoid malignancies. After careful evaluation in several EQA rounds a consensus system consisting of...
relatively few categories emerged (Table 5). Once again, the more
detailed conclusions are optional.
In case of poor DNA quality or if profiles in the Ig or TCR targets
are not evaluable, the overall conclusion is ‘not evaluable’. When
no specific products are seen in any of the Ig or TCR targets, the
overall molecular conclusion is ‘no rearrangements in Ig/TCR
targets detected’. Pseudoclonal profiles and profiles with multiple
non-reproducible products are grouped under the conclusion ‘no
clonality detected, suggestive of low template amount’. The other
three main categories of molecular conclusions are as follows:
‘clonality detected’, ‘oligoclonality/multiple clones detected’ and
‘polyclonality detected (or no clonality detected in case of weak or
faint smears in HD analysis)’. Each of these main conclusions
comes with one or more optional conclusions that contain more
details with respect to biallelic products, minor clonal products or
an oligo/polyclonal background. Importantly, the molecular
conclusion of ‘clonality detected’ can be made, even if not all
profiles show a clonal pattern.

Validation of the EuroClonality uniform description and reporting
system
We aimed to develop a description and reporting system that
should be applicable to > 95% of diagnostic cases. To validate the
uniform system presented here, each of the EuroClonality
laboratories scored 50 consecutive cases that were submitted
for routine Ig/TCR clonality testing in their institutes. In this way,
the system was evaluated on a total of > 1150 cases, representing
> 750 B-cell clonality requests and > 620 T-cell clonality requests.
Overall, the description and reporting system was difficult to apply in only 36/1150 (3.1%) cases. Thus, applicability was above the 95% target threshold, implying that the system works well for routine clonality diagnostics in multiple centers that have harmonized techniques and interpretation. Most of the difficulties appeared to be centered around low-intensity clonal signals resulting in a description of ‘clonality’ or ‘polyclonality’ with the additional remark that a minor clone might be present. This is one of the well-known gray areas in interpretation that will be hard to completely standardize between centers.

**CONTINUING MEDICAL EDUCATION THROUGH WORKSHOPS**

Standardization and quality control is critically important for optimizing clinical diagnostics for patient management. The other important prerequisite for increasing quality of diagnostics is continuous education, not only for new laboratories but also for experienced users. Education is consequently another major aim of the EuroClonality consortium. For this reason, annual educational workshops on clonality testing are organized for the diagnostic community. These 3-day workshops are especially meant for laboratories with some experience with the multiplex PCR assays for Ig/TCR gene rearrangements that bring their problematic cases for discussion. In addition, the workshop is also relevant for those laboratories that have only just started to perform PCR-based clonality testing in acquiring a broad understanding of the technical and biological pitfalls. Apart from lectures on basic aspects on gene rearrangements and immunobiological and technical pitfalls of clonality testing, the main purpose of these workshops is to have interactive sessions between participants (pathologists or hematologists plus molecular biologists) and faculty. In the various sessions of the workshops, experts and emerging investigators present their recent findings or problems in the form of short communications and/or interactive sessions with the faculty and audience.

**Figure 7.** Examples of technical descriptions of different TCRG GS profiles. Representative examples of profiles are shown for TCRG multiplex tube A. All assays have been performed in duplicate, but owing to space constraints duplicates are only shown for some technical descriptions in which the reproducibility of the pattern is crucial for proper choice of the term.

**Figure 8.** Examples of technical descriptions of different TCRD GS profiles. Representative examples of profiles are shown for TCRD multiplex tube. All assays have been performed in duplicate, but owing to space constraints duplicates are only shown for some technical descriptions in which the reproducibility of the pattern is crucial for proper choice of the term.
For the reporting system: (i) it should address two levels, that is, (a) Ig/TCR clonality assays. At the outset several criteria were defined for uniform reporting system for describing results and conclusions of clonality testing, the EuroClonality consortium now developed a following earlier standardization of the analytical phase of Ig/TCR standardization. Clearly, two different levels are concerned with the approach that is advocated to optimize interpretation of clonality interpretation. These multidisciplinary meetings perfectly illustrate the idea of an integrated approach that is advocated to optimize interpretation of clonality interpretation. Following validation in multiple EQA rounds and consequent finetuning, we now have a consensus reporting system that fulfils all these criteria. Clearly, two different levels are concerned with the interpreting system. To use the system in reporting both HD and GS analysis results, we have defined a successful approach, although it should be stressed that some of the options are more difficult to apply to gels and will therefore be less commonly chosen for HD-based results. This especially holds true for describing the number of bands in HD analysis as there is a less direct relation between the number of bands and the number of different rearrangements, due to the presence of additional HDs between the different rearrangements and due to single-strand DNA molecules. Finally, we reached the predefined aim to design reporting guidelines that are applicable in >95% of routine cases, with only 3% of difficult cases in a large cohort of >1150 routine cases that we studied within the EuroClonality consortium. The uniform reporting system will also become available in other languages via the website (http://www.euroclonality.org). It can now be further validated in other EQA schemes and may eventually be used to judge performance of individual laboratories in this type of diagnostics.

CONFLICT OF INTEREST
The EuroClonality (BIOMED-2) consortium is an independent scientific consortium that aims at innovation, standardization and education in the field of diagnostic clonality studies. All acquired knowledge and experience are shared with the scientific and diagnostic community during lectures and educational workshops. The relevant intellectual property has been protected by the patent ‘Nucleic acid amplification primers for PCR-based clonality studies’ (PCT/NL2003/000690), which is collectively owned by the EuroClonality (BIOMED-2) consortium and licensed to InVivoScribe. The revenues of the patent are exclusively used for EuroClonality (BIOMED-2) consortium activities, such as for covering (in part) the costs of the workshop, difficult cases with respect to histopathology and molecular clonality data are presented by the participants themselves, and interpretations are discussed. These multidisciplinary meetings perfectly illustrate the idea of an integrated approach that is advocated to optimize interpretation of clonality interpretation. More details on the workshops can be found at the EuroClonality website (http://www.euroclonality.org/workshop.html).

FREQUENTLY ASKED QUESTIONS (FAQS) AND REVIEW OF DIFFICULT CASES
A FAQs section is also present on the EuroClonality website. This FAQs section contains a list of the most frequent issues from the past years, ranging from ‘detection rate of clonality tests’ to ‘software used in clonality analysis’. The FAQs have been answered by an expert team of molecular biologists routinely involved in clonality testing in a pathological or immuno-hematological setting. For questions that are not addressed in the FAQ section, EuroClonality offers an online support service. To this end, a Review Board of experts is available to respond to queries on difficult cases that pose trouble in interpretation. Scientists who wish to use this service can upload their data files and query via the EuroClonality website (http://www.euroclonality.org/Support.php). Subsequently, teams of experts from the areas of hemato-pathology and hematology-immunology will provide advice on interpretation, reporting and further testing within 10 working days. Many requests have been submitted to and addressed by the Review Board, which clearly illustrates the role that such an online service has in addition to publications, guidelines and expert opinion papers.

CONCLUSION
Following earlier standardization of the analytical phase of Ig/TCR clonality testing, the EuroClonality consortium now developed a uniform reporting system for describing results and conclusions of Ig/TCR clonality assays. At the outset several criteria were defined for the reporting system: (i) it should address two levels, that is, (a) technical description of individual (multiplex) PCR results and (b) overall molecular conclusion for B and T cells; (ii) it should be useful for reporting both HD gel profiles and GS profiles; and (iii) the system should be applicable to at least 95% of routine cases. After validation in multiple EQA rounds and consequent finetuning, we now have a consensus reporting system that fulfils all these criteria. Clearly, two different levels are concerned with the reporting system. To use the system in reporting both HD and GS analysis results, we have defined a successful approach, although it should be stressed that some of the options are more difficult to apply to gels and will therefore be less commonly chosen for HD-based results. This especially holds true for describing the number of bands in HD analysis as there is a less direct relation between the number of bands and the number of different rearrangements, due to the presence of additional HDs between the different rearrangements and due to single-strand DNA molecules. Finally, we reached the predefined aim to design reporting guidelines that are applicable in >95% of routine diagnostic cases, with only 3% of difficult cases in a large cohort of >1150 routine cases that we studied within the EuroClonality consortium. The uniform reporting system will also become available in other languages via the website (http://www.euroclonality.org). It can now be further validated in other EQA schemes and may eventually be used to judge performance of individual laboratories in this type of diagnostics.

## Table 5. The EuroClonality uniform system for molecular conclusion

| Overall technical description for all Ig or TCR targets | Molecular interpretation/conclusion | Optional: more detailed molecular interpretation |
|--------------------------------------------------------|-----------------------------------|-----------------------------------------------|
| (a) No (specific) product, poor DNA quality | Not evaluable, due to poor DNA quality | Clonality detected (biallelic products) |
| (b) No (specific) product | No rearrangement in Ig/TCR targets detected | Clonality detected (biclonality) |
| (c) Ig or TCR targets | | Clonality detected (minor clonal product) |
| (d) Clonal (… nt) | Clonality detected | Clonality detected (isolated rearrangement) |
| (e) Clonality detected (Pseudoclonal (one or more non-reproducible products)) | No clonality detected, suggestive of low template amount | Clonality detected in addition to background of B/T cells |
| (f) Multiple reproducible products (n>3) | Oligoclonality/multiple clones detected | Dominant clone in oligo/polyclonal background |
| (g) Polyclonal (not clonal) | Polyclonality detected (no clonality detected) | Polyclonality detected plus minor clone of unknown significance |
| (h) Not evaluable | Not evaluable | |

**Abbreviations:** HD, heteroduplex; Ig, immunoglobulin; IGK, IG kappa; nt, nucleotide; TCR, T-cell receptor; TCRB, TCR beta. aExamples of more detailed molecular interpretation options that can be chosen by the user. bFor IGK and TCRB loci up to four clonal products may be compatible with one clone. cIn HD analysis a polyclonal smear may not always be clearly detectable, despite specific product in agarose gel; hence this is scored as ‘not clonal.’ dFor those cases in which minor reproducible peaks/bands are detected in the polyclonal background. eIn ~5% of cases the molecular interpretation cannot be made. fClonal peaks/bands are not necessarily seen for every Ig/TCR target analyzed to reach the molecular conclusion ‘clonality detected.’
ACKNOWLEDGEMENTS

We gratefully acknowledge the technical support in the various laboratories of the members of the EuroClonality consortium. We thank Mrs Sandra de Bruin-Versteeg for help in preparing figures and Mrs Marieke Comans-Bitter for organizational support for the EQA rounds.

REFERENCES

1 Van Dongen JJM, Vulkers-Tettero IL. Analysis of Ig and TCR genes, part II. Clin Chim Acta 1991; 198: 93–174.
2 Van Krieken JHJM; Langerak AW, Macintyre EA, Kneba M, Smith JL, Garcia Sanz R et al. Improved reliability of lymphoma diagnostics via PCR-based clonality testing. Report of the BIOMED-2 Concerted Action BMHA-CT-98-3936. Leukemia 2007; 21: 201–206.
3 Dik WA, Pike-Overzet K, Weerkamp F, De Ridder D, De Haas EF, Baert MMW et al. New insights on human T-cell development by quantitative T-cell receptor gene rearrangement studies and gene expression profiling. J Exp Med 2005; 201: 1715–1723.
4 Van Zelm MC, van der Burg M, de Ridder D, Barendregt BH, de Haas EF, Reinders MJ et al. Ig gene rearrangement steps are initiated in early human precursor B cell subsets and correlate with specific transcription factor expression. J Immunol 2005; 175: 5912–5922.
5 Van Dongen JJM, Hooijaaks H, Michiels J, Grosveld G, de Klein A, van der Kwast TH et al. Richter’s syndrome with different immunoglobulin light chains and different heavy chain gene rearrangements. Blood 1984; 64: 571–575.
6 Cleary ML, Chao J, Warmke R, Sklar J. Immunoglobulin gene rearrangement as a diagnostic criterion of B-cell lymphoma. Proc Natl Acad Sci USA 1984; 81: 593–597.
7 Van Dongen JJM. Analysis of immunoglobulin genes and T cell receptor genes as a diagnostic tool for the detection of lymphoid malignancies. Neth J Med 1987; 31: 201–209.
8 Deane M, Norton JD. Detection of immunoglobulin gene rearrangement in B lymphoid malignancies by polymerase chain reaction gene amplification. Br J Haematol 1990; 74: 251–256.
9 Diss TC, Peng H, Motherspoon AC, Isaacson PG, Pan L. Detection of monoclonality in low-grade B-cell lymphomas using the polymerase chain reaction is dependent on primer selection and lymphoma type. J Pathol 1993; 169: 291–295.
10 Wood GS, Tung RM, Haefner AC, Crooks CF, Liao S, Orozco R et al. Detection of clonal T-cell receptor gamma gene rearrangements in early mycosis fungoides/Sezary syndrome by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR/DGGE). J Invest Dermatol 1994; 103: 34–41.
11 Theodorou I, Delfau-Larue MH, Bigorgne C, Lahet C, Cochet G, Bagot M et al. Cutaneous T-cell infiltrates: analysis of T-cell receptor gamma gene rearrangement by polymerase chain reaction and denaturing gradient gel electrophoresis. Blood 1995; 86: 305–310.
12 Greiner TC, Raffeld M, Lutz C, Dick F, Jaffle E. Analysis of T cell receptor-gamma gene rearrangements by denaturing gradient gel electrophoresis of GC-clamped polymerase chain reaction products. Correlation with tumor-specific sequences. Am J Pathol 1995; 146: 46–55.
13 Dippel E, Assaf C, Hummel M, Schrag HJ, Stein H, Goerdt S et al. Clonal T-cell receptor-gamma chain gene rearrangement by PCR-based GeneScan analysis in advanced cutaneous T-cell lymphoma: a critical evaluation. J Pathol 1999; 188: 146–154.
14 Assaf C, Hummel M, Dippel E, Goerdt S, Muller HH, Anagnostopoulos I et al. High detection rate of T-cell receptor beta chain rearrangements in T-cell lymphoproliferations by family specific polymerase chain reaction in combination with the GeneScan technique and DNA sequencing. Blood 2000; 96: 640–646.
15 Van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMHA-CT-98-3936. Leukemia 2003; 17: 2257–2317.
16 Brüggemann M, White H, Gaulard P, Garcia-Sanz R, Gameiro P, Oeschger S et al. Powerful strategy for PCR-based clonality assessment in T-cell malignancies. Report of the BIOMED-2 Concerted Action BMHA-CT-98-3936. Leukemia 2007; 21: 215–221.
17 Evans PAS, Pott C, Groenen PJTA, Salles G, Davi F, Berger F et al. Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BMHA-CT-98-3936. Leukemia 2007; 21: 207–214.
18 Langerak AW, Molina TJ, Lavender FL, Pearson D, Flohr T, Sambade C et al. PCR-based clonality testing in tissue samples with reactive lymphoproliferations: usefulness and pitfalls. A study from the BIOMED-2 Concerted Action BMHA-CT-98-3936. Leukemia 2007; 21: 222–229.
biclonality versus intraclonal evolution of a single tumor cell clone. *Haematologica* 2006; 91: 331–339.

45 Nam-Cha SH, San-Millán B, Mollejo M, García-Cosío M, Garjio G, Gomez M et al. Light-chain-restricted germinal centres in reactive lymphadenitis: report of eight cases. *Histopathology* 2008; 52: 436–444.

46 Harris S, Bruggemann M, Groenen PJTA, Schuuring E, Langerak AW, Hodges E. Clonality analysis in lymphoproliferative disease using the BIOMED-2 multiplex PCR protocols; experience from the EuroClonality group EQA scheme. *J Hematopathol* 2012; 5: 91–98.

47 Szczepański T, Beishuizen A, Pongers-Willems M, Hählen K, Van Wering ER, Wijkhuijs AJ et al. Cross-lineage T cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B acute lymphoblastic leukemias: alternative PCR targets for detection of minimal residual disease. *Leukemia* 1999; 13: 196–205.

48 Rombout PDM, Diss TC, Hodges E, Hummel M, Van Dongen JJM, Langerak AW et al. The EuroClonality website: information, education and support on clonality testing. *J Hematopathol* 2012; 5: 99–103.

This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/